{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T17:53:35Z","timestamp":1743011615620},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejps.2014.07.005","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T20:30:25Z","timestamp":1405715425000},"page":"147-153","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects"],"prefix":"10.1016","volume":"63","author":[{"given":"M.","family":"Hoch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wilbraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Brossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dingemanse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2014.07.005_b0005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/0022034510389178","article-title":"Dissecting the role of the S1P\/S1PR axis in health and disease","volume":"90","author":"Aarthi","year":"2011","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.ejps.2014.07.005_b0010","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J. Med. Chem."},{"issue":"Suppl. 1","key":"10.1016\/j.ejps.2014.07.005_b0015","first-page":"S93","article-title":"Effects of three different up-titration regimens of ponesimod, a selective S1P1 receptor agonist, on heart rate","volume":"91","author":"Brossard","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2014.07.005_b0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0025","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.244","article-title":"[Epub ahead of print]. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: Favorable impact of dose up-titration","author":"Brossard","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.54.2.265","article-title":"International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature","volume":"54","author":"Chun","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejps.2014.07.005_b0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2014.07.005_b0040","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.ejps.2014.07.005_b0045","unstructured":"Gilenya Prescribing Information. Novartis. May 2012."},{"key":"10.1016\/j.ejps.2014.07.005_b0050","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/14656561003769866","article-title":"Fingolimod for relapsing multiple sclerosis: an update","volume":"11","author":"Horga","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2014.07.005_b0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.biochem.73.011303.073731","article-title":"Lysophospholipid receptors: signaling and biology","volume":"73","author":"Ishii","year":"2004","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejps.2014.07.005_b0060","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2014.07.005_b0065","first-page":"169","volume":"49","author":"Khasnis","year":"2003","journal-title":"J. Postgrad. Med."},{"key":"10.1016\/j.ejps.2014.07.005_b0070","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0091270004264165","article-title":"Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects","volume":"44","author":"Kovarik","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0075","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1177\/1352458512438456","article-title":"Sudden unexpected death on fingolimod","volume":"18","author":"Lindsey","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2014.07.005_b0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"4 suppl","key":"10.1016\/j.ejps.2014.07.005_b0085","first-page":"49","article-title":"Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Olsson","year":"2012","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.ejps.2014.07.005_b0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2014.07.005_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00228-013-1625-2","article-title":"Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive","volume":"70","author":"Reyes","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0100","doi-asserted-by":"crossref","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2014.07.005_b0105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/0091270006289853","article-title":"FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects","volume":"46","author":"Schmouder","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00228-011-1146-9","article-title":"Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers","volume":"68","author":"Schmouder","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2014.07.005_b0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00003088-200342020-00001","article-title":"The influence of sex on pharmacokinetics","volume":"42","author":"Schwartz","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2014.07.005_b0120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1084\/jem.20091343","article-title":"Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics","volume":"207","author":"Thangada","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejps.2014.07.005_b0125","doi-asserted-by":"crossref","first-page":"e1360","DOI":"10.1136\/bmj.e1360","article-title":"Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug","volume":"344","author":"Wise","year":"2012","journal-title":"BMJ"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714003017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098714003017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T09:28:06Z","timestamp":1538386086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098714003017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":25,"alternative-id":["S0928098714003017"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2014.07.005","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2014.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}